The enterprise value is 21% below market value. Any reason for this?
The company dependent on acquisition for growth and it has some integration issues with Applied Bio.I think it has a good chance of ending the year in high 50s.
The technology is good- they just don't know how to get anything done internal with the incompetent management. Their only approach is acquisition- don't need ANY high priced scientists on the bloated payroll.
i agree i have 2 other pharm stock ILMN and ALXN and just have to have LIFE too, bought 300 today at 47.96. hope it goes up to ALXN.